OS Therapies (OSTX) Short-Term Debt issuances (2024)
OS Therapies' (OSTX) quarterly Short-Term Debt issuances came in at $150000.0 in Q2 2024, up 50.0% on a QoQ basis from $100000.0 in Q1 2024.
OS Therapies (OSTX) Short-Term Debt issuances (2024) Analysis & Trends
OS Therapies (OSTX) has 1 years of Short-Term Debt issuances data on file, last reported at $150000.0 in Q2 2024.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to $150000.0 in Q2 2024, while the trailing twelve-month figure through Dec 2024 was $250000.0 (changed N/A YoY) and the FY2024 annual result came in at $250000.0, changed N/A from the prior year.
- Short-Term Debt issuances rose to $150000.0 in Q2 2024, from $100000.0 in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $150000.0 in Q2 2024 to a low of $100000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 150,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |